Vaccines for viral hemorrhagic fevers--progress and shortcomings.
Vaccines for viral hemorrhagic fevers--progress and shortcomings.
复制标题
DOI：
10.1016/j.coviro.2013.04.007
复制
发表时间：
2013-06
影响因子：
5.9
通讯作者：
Feldmann, Heinz
中科院分区：
文献类型：
--
作者：
Falzarano, Darryl;Feldmann, Heinz
除了少数例外，针对引起出血热的病毒的疫苗仍然不可用或缺乏有效性的充分证明。在过去十年中，这并不是因为缺乏开发针对高致病性病毒的疫苗平台的能力，而是缺乏对有可能成为成功疫苗的平台进行投资的意愿/兴趣。这方面的两个例外是针对登革热病毒和裂谷热病毒的疫苗，这两种病毒最近分别在提出新的和改进的疫苗方面取得了重大进展。丝状病毒和拉沙病毒的实验性疫苗确实存在，但由于缺乏经济利益以及只能在临床试验中评估的部分或不明确的保护相关性/机制而受到阻碍。
With a few exceptions, vaccines for viruses that cause hemorrhagic fever remain unavailable or lack well-documented efficacy. In the past decade this has not been due to a lack of the ability to develop vaccine platforms against highly pathogenic viruses, but rather the lack of will/interest to invest in platforms that have the potential to become successful vaccines. The two exceptions to this are vaccines against Dengue virus and Rift Valley Fever virus, which recently have seen significant progress in putting forward new and improved vaccines, respectively. Experimental vaccines for filoviruses and Lassa virus do exist but are hindered by a lack of financial interest and only partially or ill-defined correlates/mechanisms of protection that could be assessed in clinical trials.
登录
查看更多内容
影响因子：
6.7
作者：
Grard G;Fair JN;Lee D;Slikas E;Steffen I;Muyembe JJ;Sittler T;Veeraraghavan N;Ruby JG;Wang C;Makuwa M;Mulembakani P;Tesh RB;Mazet J;Rimoin AW;Taylor T;Schneider BS;Simmons G;Delwart E;Wolfe ND;Chiu CY;Leroy EM
通讯作者：
Leroy EM
影响因子：
3.7
作者：
Gorchakov, Rodion;Volkova, Eugenia;Frolov, Ilya
通讯作者：
Frolov, Ilya
影响因子：
5.4
作者：
Bukreyev, Alexander;Rollin, Pierre E.;Sanchez, Anthony
通讯作者：
Sanchez, Anthony
影响因子：
3.8
作者：
Fichet-Calvet, Elisabeth;Rogers, David John
通讯作者：
Rogers, David John
影响因子：
5.5
作者：
de Boer, S. M.;Kortekaas, J.;Bosch, B. J.
通讯作者：
Bosch, B. J.